IGMS
IGM Biosciences Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci
Market Cap: 402 Million
Primary Exchange: NASDAQ
Website: http://igmbio.com/
Shares Outstanding: 32.9 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.158826580807121
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 996 trading days
From: 2021-02-09 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|